Impact of COVID-19 Infection on the Outcome of Patients With Ischemic Stroke.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 31 8 2021
medline: 15 12 2021
entrez: 30 8 2021
Statut: ppublish

Résumé

We evaluated whether stroke severity, functional outcome, and mortality are different in patients with ischemic stroke with or without coronavirus disease 2019 (COVID-19) infection. A prospective, observational, multicentre cohort study in Catalonia, Spain. Recruitment was consecutive from mid-March to mid-May 2020. Patients had an acute ischemic stroke within 48 hours and a previous modified Rankin Scale (mRS) score of 0 to 3. We collected demographic data, vascular risk factors, prior mRS score, National Institutes of Health Stroke Scale score, rate of reperfusion therapies, logistics, and metrics. Primary end point was functional outcome at 3 months. Favourable outcome was defined depending on the previous mRS score. Secondary outcome was mortality at 3 months. We performed mRS shift and multivariable analyses. We evaluated 701 patients (mean age 72.3±13.3 years, 60.5% men) and 91 (13%) had COVID-19 infection. Median baseline National Institutes of Health Stroke Scale score was higher in patients with COVID-19 compared with patients without COVID-19 (8 [3-18] versus 6 [2-14], Patients with ischemic stroke and COVID-19 infection have more severe strokes and a higher mortality than patients with stroke without COVID-19 infection. However, functional outcome is comparable in both groups.

Sections du résumé

BACKGROUND AND PURPOSE
We evaluated whether stroke severity, functional outcome, and mortality are different in patients with ischemic stroke with or without coronavirus disease 2019 (COVID-19) infection.
METHODS
A prospective, observational, multicentre cohort study in Catalonia, Spain. Recruitment was consecutive from mid-March to mid-May 2020. Patients had an acute ischemic stroke within 48 hours and a previous modified Rankin Scale (mRS) score of 0 to 3. We collected demographic data, vascular risk factors, prior mRS score, National Institutes of Health Stroke Scale score, rate of reperfusion therapies, logistics, and metrics. Primary end point was functional outcome at 3 months. Favourable outcome was defined depending on the previous mRS score. Secondary outcome was mortality at 3 months. We performed mRS shift and multivariable analyses.
RESULTS
We evaluated 701 patients (mean age 72.3±13.3 years, 60.5% men) and 91 (13%) had COVID-19 infection. Median baseline National Institutes of Health Stroke Scale score was higher in patients with COVID-19 compared with patients without COVID-19 (8 [3-18] versus 6 [2-14],
CONCLUSIONS
Patients with ischemic stroke and COVID-19 infection have more severe strokes and a higher mortality than patients with stroke without COVID-19 infection. However, functional outcome is comparable in both groups.

Identifiants

pubmed: 34455823
doi: 10.1161/STROKEAHA.121.034883
pmc: PMC8607902
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3908-3917

Références

JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
JAMA Cardiol. 2020 Jul 1;5(7):751-753
pubmed: 32219362
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Stroke. 2020 Jul;51(7):2002-2011
pubmed: 32432996
Front Med (Lausanne). 2021 Feb 05;8:620044
pubmed: 33634150
Stroke. 2020 Aug;51(8):2307-2314
pubmed: 32466738
Stroke. 2020 Jul;51(7):1991-1995
pubmed: 32438895
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Int J Stroke. 2020 Jul;15(5):540-554
pubmed: 32362244
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Neurol. 2020 Aug;267(8):2185-2192
pubmed: 32436105
Neurology. 2020 Dec 15;95(24):e3373-e3385
pubmed: 32934172
Aging (Albany NY). 2020 May 29;12(10):9959-9981
pubmed: 32470948
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Stroke. 2011 May;42(5):1482-8
pubmed: 21474812
J Microbiol Immunol Infect. 2021 Apr;54(2):164-174
pubmed: 32513617
Lancet Infect Dis. 2021 Jun;21(6):e163-e169
pubmed: 33301725
Stroke. 2020 Dec;51(12):3570-3576
pubmed: 33106109
Stroke. 2020 Jul;51(7):e124-e127
pubmed: 32396456
Stroke. 2020 Jul;51(7):1924-1926
pubmed: 32496937
Stroke Vasc Neurol. 2020 Sep;5(3):279-284
pubmed: 32616524
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):889-891
pubmed: 32354768
Stroke. 2020 Jul;51(7):2219-2223
pubmed: 32466735
Neurology. 2020 Aug 25;95(8):e1060-e1070
pubmed: 32482845
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Stroke. 2020 Jul;51(7):1996-2001
pubmed: 32432997
Stroke. 2020 Jun;51(6):1910-1912
pubmed: 32233972
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504

Auteurs

Joan Martí-Fàbregas (J)

Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (J.M.-F., D.G.-A., R.D.-M., A.M.-D., L.P.-S., M.G.-J., P.C.-R.).

Daniel Guisado-Alonso (D)

Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (J.M.-F., D.G.-A., R.D.-M., A.M.-D., L.P.-S., M.G.-J., P.C.-R.).

Raquel Delgado-Mederos (R)

Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (J.M.-F., D.G.-A., R.D.-M., A.M.-D., L.P.-S., M.G.-J., P.C.-R.).

Alejandro Martínez-Domeño (A)

Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (J.M.-F., D.G.-A., R.D.-M., A.M.-D., L.P.-S., M.G.-J., P.C.-R.).

Luis Prats-Sánchez (L)

Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (J.M.-F., D.G.-A., R.D.-M., A.M.-D., L.P.-S., M.G.-J., P.C.-R.).

Marina Guasch-Jiménez (M)

Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (J.M.-F., D.G.-A., R.D.-M., A.M.-D., L.P.-S., M.G.-J., P.C.-R.).

Pere Cardona (P)

Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Spain (P.C., A.N.-G.).

Ana Núñez-Guillén (A)

Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Spain (P.C., A.N.-G.).

Manuel Requena (M)

Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain (M. Requena, M. Rubiera, M.O.).

Marta Rubiera (M)

Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain (M. Requena, M. Rubiera, M.O.).

Marta Olivé (M)

Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain (M. Requena, M. Rubiera, M.O.).

Alejandro Bustamante (A)

Department of Neurology, Hospital Germans Trias i Pujol, Badalona, Spain (A.B., M.G.).

Meritxell Gomis (M)

Department of Neurology, Hospital Germans Trias i Pujol, Badalona, Spain (A.B., M.G.).

Sergio Amaro (S)

Department of Neurology, Hospital Universitari Clinic, Barcelona, Spain (S.A., L.L.).

Laura Llull (L)

Department of Neurology, Hospital Universitari Clinic, Barcelona, Spain (S.A., L.L.).

Xavier Ustrell (X)

Department of Neurology, Hospital Universitari Joan XXIII, Tarragona, Spain (X.U., G.C.d.O., L.S.).

Gislaine Castilho de Oliveira (G)

Department of Neurology, Hospital Universitari Joan XXIII, Tarragona, Spain (X.U., G.C.d.O., L.S.).

Laia Seró (L)

Department of Neurology, Hospital Universitari Joan XXIII, Tarragona, Spain (X.U., G.C.d.O., L.S.).

Manuel Gomez-Choco (M)

Department of Neurology, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain (M.G.-C., L.M.).

Luis Mena (L)

Department of Neurology, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain (M.G.-C., L.M.).

Joaquín Serena (J)

Department of Neurology, Hospital Universitari Dr. Josep Trueta, Girona, Spain (J.S., S.B.V.).

Saima Bashir Viturro (S)

Department of Neurology, Hospital Universitari Dr. Josep Trueta, Girona, Spain (J.S., S.B.V.).

Francisco Purroy (F)

Stroke Unit, Hospital Universitari Arnau de Vilanova, Lleida, Spain (F.P., M.V.).

Mikel Vicente (M)

Stroke Unit, Hospital Universitari Arnau de Vilanova, Lleida, Spain (F.P., M.V.).

Ana Rodríguez-Campello (A)

Department of Neurology, Hospital del Mar, Barcelona, Spain (A.R.-C., A.O., A.M.).

Angel Ois (A)

Department of Neurology, Hospital del Mar, Barcelona, Spain (A.R.-C., A.O., A.M.).

Esther Catena (E)

Department of Neurology, Hospital comarcal de l'Alt Penedès, Vilafranca del Penedès, Spain (E.C.).

Maria Carmen Garcia-Carreira (M)

Department of Neurology, Hospital Universitari Parc Taulí, Sabadell, Spain (M.C.G.-C., O.B.).

Oriol Barrachina (O)

Department of Neurology, Hospital Universitari Parc Taulí, Sabadell, Spain (M.C.G.-C., O.B.).

Ernest Palomeras (E)

Department of Neurology, Hospital de Mataró, Spain (E.P.).

Jerzky Krupinski (J)

Department of Neurology, Hospital Universitari Mútua de Terrassa, Spain (J.K., M.A.).

Marta Almeria (M)

Department of Neurology, Hospital Universitari Mútua de Terrassa, Spain (J.K., M.A.).

Josep Zaragoza (J)

Department of Neurology, Hospital de Tortosa Verge de la Cinta, Spain (J.Z., P.E.).

Patricia Esteve (P)

Department of Neurology, Hospital de Tortosa Verge de la Cinta, Spain (J.Z., P.E.).

Dolores Cocho (D)

Department of Neurology, Hospital General de Granollers, Spain (D.C.).

Antia Moreira (A)

Department of Neurology, Hospital del Mar, Barcelona, Spain (A.R.-C., A.O., A.M.).
Department of Neurology, Hospital d'Igualada, Spain (A.M.).

Cecile van Eendenburg (C)

Department of Neurology, Hospital de Figueres, Spain (C.v.E.).

Javier Emilio Codas (J)

Department of Neurology, Consorci Sanitari de Terrassa, Spain (J.E.C.).

Natalia Pérez de la Ossa (N)

Stroke Program, Agency for Health Quality and Assessment of Catalonia, Barcelona, Spain (N.P.d.l.O., M.S.).

Mercè Salvat (M)

Stroke Program, Agency for Health Quality and Assessment of Catalonia, Barcelona, Spain (N.P.d.l.O., M.S.).

Pol Camps-Renom (P)

Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (J.M.-F., D.G.-A., R.D.-M., A.M.-D., L.P.-S., M.G.-J., P.C.-R.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH